$CFMS The company is a biotechnology company operating in the technology sector. It sells its proprietary technology platform. The company sells and develops joint replacement products.
These replacements can be highly customized, as a result, the company offers much better outcomes for patients. This system has shown high clinical efficacy and faster recovery times compared to traditional implants currently available.
Today, 10.05, the company announced big news, as it received approval for its developed 510K knee replacement system from the U.S. Food and Drug Administration. The system will allow for the expansion of the technology to a wide range of orthopedic needs.
Analyst coverage: Oppenheimer this morning gives a price target of $3, an upside of about 200%.
Canaccord Gen gives a target of $2, an upside of about 100%.
Technically: Current price: $0.8812 First target (in my opinion): $1.20 Second target (in my opinion): $2.7 Stop loss: $0.70 Debt-to-equity ratio: 0.23 The company has $104 million in cash, which should cover expenses for the coming year, reducing the chance of an offering.
Note this is a penny stock. It is higher risk!!
Personal opinion only! Anyone using this information does so at their own discretion and personal responsibility only